Gilead Sciences Files for EU Approval of Remdesivir for COVID-19

The European Medicines Agency said it is giving a fast-track review to a conditional marketing authorization request from Gilead Sciences for using remdesivir to treat COVID-19 patients.

The agency said it may grant the authorization within weeks, as it has already completed a review of preliminary trial data.

The FDA granted remdesivir an Emergency Use Authorization on May 1 for treatment of hospitalized COVID-19 patients with severe disease.